Table 1.
Correlation of centrosome aberrations in different types of tumors
| Cancer type | N | Co-expression of cancer marker | Histology/other information | References |
|---|---|---|---|---|
| Breast | 362 | Pericentrin, Ki67 | Higher CA in higher stage and grade tumors; higher CA and ploidy or acentriolar in triple negative and HER2 tumors | Denu et al85 |
| Prostate | 99 | ⇑ Nek2 | Correlated with a Gleason score >8, metastasis, PSA failure, and OS | Zeng et al86 |
| Gastric | 186 | ⇑ TACC3 | Extracapsular extension and tumor relapse, shortened OS and DFS | Yun et al87 |
| Bladder (NMIBC) | 78 | Pericentrin | CA was correlated with disease progression | Miyachika et al88 |
| Breast | 31 | ⇑ Plk4 ⇓ KLF14 | Not provided | Fan et al89 |
| Colon | 15 | |||
| Esophageal | 78 | ⇑ Aurora A | Better prognosis regarding clinical response to chemoradiation | Tamotsu et al90 |
| Pancreas | 133 | PP4C | Correlated with distal metastasis and poor survival in patients in stage II | Weng et al91 |
| Ovarian | 43 high grade SC 37 STIC | CCNE1 | Higher CA in SC compared with STIC | Kuhn et al92 |
Abbreviations: DFS, disease free survival; N, sample size; NMIBC, non-muscle invasive bladder cancer; OS, overall survival; PSA, prostate-specific antigen; SC, serous carcinoma; STIC, serous tubal intraepithelial carcinoma; CA, centrosome amplification.